Sponsors (2)
The bill improves biosafety, traceability, and federal coordination for high‑risk agents—strengthening outbreak response and focusing oversight—but does so at the cost of higher compliance and administrative burdens, new security/privacy risks for sensitive data, and additional public and private expenses that could burden researchers, labs, and taxpayers.
Researchers, hospitals, and public‑health officials gain a centralized federal log of transfers for high‑risk agents that improves traceability and speeds outbreak investigation and containment.
BSL‑3+ labs will be subject to periodic strategic evaluations and national standards, which should reduce the risk of lab accidents, misuse, and unsafe practices.
A federally maintained, annually updated list of highly pathogenic agents together with targeted audit authorities creates clearer rules for distributors and focuses enforcement on higher‑risk transactions.
Researchers, university labs, hospitals, and distributors will face greater recordkeeping, reporting, audit, and compliance obligations that increase administrative and operational costs and could divert funds from research or raise prices/limit availability of benign materials.
Requiring government‑grade photo ID and criminal penalties for false statements may deter legitimate buyers and complicate routine transfers for small labs, repositories, and some researchers.
Consolidated logs of transfers and any public listing of facility identities/addresses create sensitive datasets that, if stolen or widely released, could be exploited by malicious actors and raise biosecurity/privacy risks.
Based on analysis of 3 sections of legislative text.
Requires distributors to keep electronic logbooks of transfers of designated highly pathogenic agents and directs a federal entity to evaluate and set national standards for high-containment labs.
Introduced March 26, 2026 by Catherine Marie Cortez Masto · Last progress March 26, 2026
Requires distributors who sell or transfer designated "highly pathogenic agents" to keep an electronic logbook of every sale, lease, loan, or transfer and to verify purchaser identity and intended use before transfer. Directs a senior White House official to pick one federal entity to do recurring strategic reviews of U.S. high-containment laboratories, create national standards for their design and operation, maintain a federal public-health biosafety contact team, and study creating a public database of high-containment labs. Sets deadlines for initial actions (an initial list of covered agents within six months of enactment and periodic reviews thereafter), requires interagency consultation when creating lists and standards, and mandates reports to the President and Congress on evaluations, recommendations, and the feasibility study for a lab database.